Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986325 in Healthy Participants and Primary Sjögren's Syndrome
NCT04684654Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BMS-986325 in primary Sjögren's syndrome (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events (AEs) up to 137 days, Incidence of clinically significant changes in clinical laboratory results: Hematology tests up to 137 days and 17 more. Started Feb 2021; status: terminated.
02
Drugs
BMS-986325
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04684654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684654.